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Summary Diabetes mellitus may be associated with increased lipid peroxidation which may contribute to long-term tissue damage. To test this hypothesis, we measured hydroperoxides (ROOHs) as well as a -tocopherol in plasma from healthy subjects and individuals with non-insulin-dependent diabetes mellitus (NIDDM) (n = 41 and 87, respectively). ROOHs were analysed using the ferrous oxidation with xylenol orange version II (FOX2) assay in conjunction with a specific ROOH reductant, triphenylphosphine. a -Tocopherol was analysed by HPLC with fluorimetric detection. NIDDM patients had lower cholesterol standardised a -tocopherol levels as compared to control subjects (3.3 ± 1.0 vs 5.1 ± 2.3 (mmol/l)/(mmol/l); p < 0.0005, Mann-Whitney test): range (1.5-6.5 vs 1.9-13.0, respectively). Plasma ROOHs were substantially higher in the diabetic subjects compared to those of the control subjects (9.4 ± 3.3 vs 4.1 ± 2.2 m mol/l; p < 0.0005 Mann-Whitney test: range 2.7-16.8 vs 0. 4-10.3, respectively) . ROOH/cholesterol standardised a -tocopherol ratio was significantly higher in the diabetic patients compared to control subjects (3.2 ± 1.6 vs 0.9 ± 0.6; p < 0.0005, Mann-Whitney test: range 0.7-8.3 and 0.1-2.7, respectively). Plasma levels of ROOHs and a -tocopherol were similar in diabetic patients with or without complications as well as in smokers and non-smokers. The present study confirms previous findings from this laboratory that NIDDM is associated with increased oxidative stress as assessed by plasma ROOHs. Increased oxidative stress in diabetic patients appears to be related to the underlying metabolic abnormalities in diabetes, rather than to the complications of this disease. We therefore suggest that oxidative stress is an early stage in the disease pathology, which may contribute to the development of complications. [Diabetologia (1997) 40: 647-653] Keywords NIDDM, lipid hydroperoxides, vitamin E, oxidative stress.
as compared to control subjects. Dense LDL is more readily oxidised than more buoyant LDL [9] . LDL from diabetic patients also has higher levels of advanced glycation end products as compared to control subjects [10] . Freshly isolated very low density lipoprotein (VLDL) and LDL from diabetic rats is more oxidisable, as well as more cytotoxic to fibroblast cells, than those from non-diabetic rats [11] . It has also been shown that the extent of lipoprotein peroxidation and toxicity is inhibited by treatment of the rats with probucol or vitamin E (a-tocopherol) [11] . Depletion of serum and cellular antioxidants including a -tocopherol, ascorbate and thiols also occurs in NIDDM patients, consistent with enhanced consumption due to oxidation [12] .
Despite the biochemical importance of oxidative stress its measurement in vivo has been difficult [13] . This problem has been approached in two ways: 1) measurement of reaction products of oxidative damage such as lipid peroxides; and 2) measurement of the depletion of antioxidants. Enhanced lipid peroxidation in diabetic patients has been reported using thiobarbituric acid reactive substances (TBARS) as an assay [14] [15] [16] [17] [18] . However, interpretation of the relationship between lipid peroxidation and diabetes has yielded contradictory results [14, 15, 18, 19] . The simple TBARS assay measures many parameters in addition to lipid peroxidation and is affected by the lipid content of the sample [20] . Thus, it is unclear to what extent plasma lipoprotein peroxidation assessed by this method accounts for biological changes associated with oxidative stress. Data are also conflicting regarding a -tocopherol status in diabetic subjects. Some studies report no changes, others a decrease and yet others an increase [21] [22] [23] . One problem in such studies is that failure to lipid-standardise a -tocopherol can give misleading results in hyperlipidaemic patients. Recently, we used the ferrous oxidation with xylenol orange (FOX) assay, coupled with the selective hydroperoxide reductant triphenylphosphine (TPP), to determine levels of lipid hydroperoxides (ROOH) in NIDDM [24] . For 22 individuals with NIDDM, a mean level of 9.04 ± 4.3 m mol/l was recorded. This level was higher (p < 0.0005; separate variance test) than plasma ROOH from control subjects (3.76 ± 2.48 m mol/l). There was no difference between levels of plasma malondialdehyde using the TBA-test between NIDDM or control subjects (1.00 ± 0.70 vs 1.21 ± 0.62 m mol/l; p < 0.1). The current study was undertaken to assess plasma lipid hydroperoxides and a -tocopherol concentration in larger groups of NIDDM and healthy control subjects (87 and 41 individuals, respectively) and have attempted to relate these parameters to the presence of complications.
We also propose that ROOH/cholesterol standardised a -tocopherol ratio is a clinically more relevant measure of oxidative stress in diabetes.
Subjects, materials and methods
Subject recruitment and characterization. We recruited 87 NIDDM subjects from well-characterized patients attending the University College London Hospitals' Diabetic Service. Patients were assessed for the presence of diabetic complications with particular reference to large vessel disease. History of myocardial infarction substantiated by ECG and enzyme changes was noted. Presence of angina was confirmed by exercise ECG and exercise thallium test. Retinopathy was determined by direct ophthalmoscopy through a dilated pupil. Peripheral neuropathy was assessed clinically using the scoring system described by Volk et al. [25] which provides a reasonable and quantifiable estimate of nerve function measured neurophysiologically. Urinary albumin excretion rate (AER:mg/min) was measured by an enzyme linked immunoassay and calculated as the mean of three timed overnight urine collections [26] . To allow unequivocal group separation normoalbuminuria was defined as below 10 m g/min, microalbuminuria as m g/min and macroproteinuria as above 250 m g/min. Patients were subdivided into two groups withand without evidence of complications (n = 49 and 38, respectively). Primary complications include retinopathy, neuropathy, nephropathy, chronic heart disease and stroke (n = 26, 6, 8, 5, 3 and 1, respectively). Non-smokers (n = 61) were defined as those individuals who had never smoked or claimed to have stopped smoking at least 3 years prior to plasma sampling for the study. Diabetic subjects were treated by diet alone or by diet plus oral hypoglycaemic agents (metformin and/or tolbutamide). Healthy volunteers (n = 41) were recruited from the Rayne Institute, UCL, Medical School. None of the control subjects was a smoker, on any special diet, taking vitamin E or any medication related to atherosclerosis or diabetes before taking part in this study. This study was approved by the joint UCL/UCH ethical committee of the UCL, Medical School.
Reagents. Ammonium ferrous sulphate, hydrogen peroxide (H 2 O 2 ) and butylated hydroxytoluene were obtained from Sigma Chemical Company (Poole, Dorset, UK). Xylenol orange [o-cresolsulphonphthalein-3, 3-bis(methyliminodiacetic acid sodium salt)] and TPP were purchased from Aldrich (Gillingham, Dorset, UK).
Preparation of plasma.
Blood was collected by venipuncture into sampling vials (10 ml) containing heparin. Plasma was obtained by centrifugation at 2000 g for 10 min at room temperature. For the ROOH assay, plasma was kept on ice and was analysed within 3 h.
Clinical laboratory measurements.
Fasting plasma glucose was measured by using a glucose oxidase method. Glycated haemoglobin A1 (Hb A1 ) was measured by agarose gel electrophoresis [27] . Total plasma cholesterol was measured using the Cholesterol-C high performance CHOD-PAP method (Boehringer Mannheim GmbH; Diagnostics and Biochemicals, East Sussex, UK). Total triglyceride was measured using the GPO-PAP high-performance enzymatic colorimetric test (Boehringer Mannheim GmbH).
Measurement of indices of lipid peroxidation
Hydroperoxides. Whole plasma ROOHs were determined using the ferrous oxidation in xylenol orange, Version II (FOX assay for lipid ROOHs) [24, 28] . Briefly, 90-ml aliquots of plasma were transferred into 6 (1.5 ml) microcentrifuge vials; 10 m l of 10 mmol/l TPP in methanol was added to 3 vials to remove ROOHs; 10 m l of methanol was added to the remaining 3 vials. This generated blank and test samples, respectively. All vials were then vortexed and incubated at room temperature for 30 min prior to the addition of 900 m l FOX2 reagent with mixing. After incubation at room temperature for a further 30 min, the vials were centrifuged at 12000 g at 25°C for 10 min. Absorbance of the supernatant was then determined at 560 nm. ROOH content in the plasma samples was determined as a function of the mean absorbance difference of samples with and without elimination of ROOH by TPP. The standard deviation was taken as the larger of the standard deviations of the measurements obtained with or without TPP treatment. [24] . We decided to cholesterol standardise plasma a -tocopherol levels because: a) a -tocopherol is mainly transported by cholesterol; b) cholesterol levels are less subject to diurnal variation than total lipids [29] .
Statistical analysis was performed using the Unistat Desktop Statistical Analysis package version 3 (Unistat Ltd, London, UK) and NCSS Version 6.0 (Number Cruncher Statistical Systems, Kaysville, Utah, USA). Data are expressed as mean ± SD. The results are expressed as mean with 95 % confidence intervals since data are skewed. A non-parametric test was used to evaluate the difference in plasma biochemical parameters in healthy and diabetic subjects. P-values less than 0.05 (two-tailed) were considered significant. Table 1 shows the clinical characteristics of the patients and control subjects as well as the differences in levels of plasma ROOHs, a -tocopherol, cholesterol standardised a -tocopherol and ROOHs/cholesterol standardised a -tocopherol. The NIDDM individuals had elevated fasting blood glucose, HbA 1 , triglycerides and cholesterol levels compared to the control subjects. Mean age of the diabetic patients was significantly higher compared to that of the control subjects [58.4 ± 14.7 vs 38.2 ± 12.3; p < 0.0005]. Since plasma ROOH levels in neither diabetic nor control subjects was explained by age [24] we did not age-standardise patients and control subjects. The data spread for plasma ROOHs in control and the diabetic subjects is shown in Figure 1 . The coefficient of variation for individual plasma samples using this method is typically less than 5 % which is in agreement with a previous study [24] .
Results
Absolute plasma a -tocopherol levels in the diabetic subjects were slightly, but significantly, lower than those of the control subjects [19.6 ± 3.3 vs [24] . ROOH concentrations in female diabetic and control subjects were (9.9 ± 3.2 vs 4.9 ± 2.3 m mol/l; p < 0.0005). The corresponding levels for males were 9.1 ± 3.3 vs 3.0 ± 1.6 m mol/l; p < 0.0005). Expression of plasma ROOH levels per unit of cholesterol standardised a -tocopherol also revealed that ROOH/cholesterol standardised a -tocopherol ratio in the NIDDM subjects was significantly elevated compared to that of the control subjects Data are mean ± SD and [range] or (normal range) (3.2 ± 1.6 vs 0.9 ± 0.6). ROOH/cholesterol standardised a -tocopherol ratio did not correlate with age, cholesterol, triglycerides or HbA 1 in diabetic or control subjects. There was, however, a relation between ROOH/cholesterol standardised a -tocopherol ratio and fasting blood glucose (Pearson's r = 0.23; p < 0.05) in the diabetic patients only (Fig. 2) .
Absolute-and cholesterol standardised plasma a -tocopherol, ROOH and ROOH/cholesterol standardised a -tocopherol ratio levels were very similar in patients with complications (including retinopathy, neuropathy, nephrophy or vascular) and without complications. Furthermore, there was no difference in absolute-and cholesterol standardised a -tocopherol, ROOHs or ROOH/cholesterol standardised a -tocopherol ratio between diabetic patients with retinopathy compared to those without the complication. The above parameters were not evaluated for individual complications as the numbers were too small. Table 2 summarises the clinical characteristics of diabetic subjects with and without complications.
Among the diabetic patients, plasma absolute-and cholesterol standardised a -tocopherol concentrations were very similar in smokers and non-smokers. On the other hand, ROOHs as well as ROOH/cholesterol a -tocopherol standardised ratios were slightly higher in non-smokers than in smokers. Table 3 gives the clinical characteristics of smokers and non-smokers.
Discussion
Oxidative stress has been proposed as a major component in the events that cause late complications in patients with diabetes mellitus. A prerequisite for animal experimental models and studies in human diabetes is sensitive and reliable laboratory tools for detecting oxidative stress. In the present cross-sectional study of well-characterised individuals with NIDDM, plasma total ROOHs were specifically measured using the FOX2-assay with TPP authentication of the signal [24, 28] .
Plasma hydroperoxide assays are divided into two catagories including total-and individual hydroperoxide classes. Individual hyroperoxide classes are measured by HPLC-linked microperoxidase -derived isoluminol chemiluminescence (CL) techniques while total values are assayed using colourometric-, chemiluminescence-or enzymatic techniques. Total plasma hydroperoxides have been estimated to be between 0.5 and 5.5 m mol/l using different techniques [30] [31] [32] [33] [34] . Using HPLC-CL assays, plasma levels of phospholipid hydroperoxides have been reported to range from 10 to 500 nmol/l [35] [36] [37] . Cholesteryl ester hydroperoxide levels are reported to be as low as 3 nmol/l [38, 39] or as high as 920 nmol/l [40] .
Some investigators have reported an association between TBARS and diabetic complications [16, 18] while other have not [14] . Jennings et al. [41] reported that elevated levels of conjugated dienes in plasma from diabetic subjects are associated with microangiopathy. MacRury et al. [15] compared different methods (conjugated dienes, TBARS and chemiluminescence) of assessing free radical activities in diabetic subjects. In each case, diabetes was associated with elevated levels of different indirect measurement of lipid peroxidation. However, they did not show any relationship between diabetic complications and plasma measures of oxidative stress. Glucose (mmol / l) Fig. 2 . Correlation between ROOH/cholesterol standardised ratio and fasting blood glucose levels in NIDDM subjects specific non-enzymatic peroxidation product derived from arachidonic acid, has been reported; association between 8-epi PGF 2 a and diabetic complications was not discussed [42] . In this study, diabetic patients had 2.3 times higher plasma lipid ROOH levels as compared to control subjects confirming previous data from our laboratory [24] . The elevated level of plasma ROOHs in the diabetic subjects was not influenced by sex, age, smoking habit or diabetic complications. Our data suggest that the elevated levels of plasma ROOH in patients are associated with the diabetes itself.
A number of studies have reported absolute or lipid standardised vitamin E concentrations in plasma from diabetic patients. Tsai et al. [22] reported no changes in absolute a -tocopherol levels whereas others have reported decreases and even increases [23, 43, 44] . In this study, diabetic patients had significantly lower levels of a -tocopherol compared to control subjects.
a -Tocopherol concentrations in the diabetic patients were still low even when the levels were expressed per unit cholesterol. These findings are similar to results of other investigators studying antioxidant vitamins in relation to risk factors in diabetic subjects [18, 45] . The sex of diabetic or control subjects had no significant influence on a -tocopherol levels. Variation in age did not explain the lower levels of plasma a -tocopherol in this population of diabetic subjects since there was no correlation between age and a -tocopherol content in NIDDM or control subjects. The change in cholesterol standardised a -tocopherol was very similar in our diabetic subjects with and without complications as well as in smokers and non-smokers. These data together suggest that the low plasma a -tocopherol status in diabetes is associated with the syndrome itself. Another factor responsible for the above abnormality in the diabetic subjects could be chronic low dietary intake of antioxidants. More research into this area is required to clarify these points.
It has been shown that whole plasma and isolated LDL from NIDDM patients are more prone to peroxidation as compared to that of control subjects; and that vitamin E supplementation decreased peroxidation of whole plasma as well as isolated lipoprotein fractions [46] [47] [48] . Diabetic platelets are postulated to be deficient in a -tocopherol and their dysfunction is partially normalised by a -tocopherol therapy [49] . Salonen et al. [50] suggested that low a -tocopherol is a risk factor for onset of NIDDM. High intake of vitamin E has been shown to be associated with a lower risk of coronary heart disease in human studies [51] [52] [53] . Thus, the decline in a -tocopherol levels in diabetic subjects may reflect part of a continuous cycle of oxidative stress and damge induced by the syndrome.
Another important point from our data is that plasma from diabetic patients had substantially higher ROOH content as compared to control subjects when the levels were expressed per unit cholesterol standardised a -tocopherol. The ROOH/cholesterol standardised a -tocopherol ratio in the diabetic patients was 3.6 times higher as compared to the control subjects; the difference in ROOH levels alone was 2.3 fold. The ROOH/cholesterol standardised a -tocopherol ratio also showed a scatter pattern but a significant association with fasting blood glucose only in the patient group; ROOH values alone did not show a relationship. We were concerned that the relationship between ROOH/cholesterol standardised a -tocopherol ratio in the diabetic patients was in fact a deterioration due to the cigarette smoking rather than fasting blood glucose. Interestingly, a strong association between ROOH/cholesterol standardised ratio and fasting blood glucose levels was found in non-smoking diabetic patients (Pearson's r = 0.36; p < 0.01); smokers did not show a relationship (Pearson's r = 0.06; p < 0.4). These findings suggest that brittleness of diabetes may determine plasma hydroperoxide concentrations. This would also be consistent with the hypothesis that unstable glycaemia rather than chronic hyperglycaemia is a major risk factor in the long-term complications of NIDDM. Therefore, we propose that this marker is a better index of oxidative stress/antioxidant status than ROOHs or a -tocopherol alone since any changes in plasma lipid peroxidation will be dependent on the degree of saturation of plasma lipids by a -tocopherol. This marker should be a useful tool in trials examining antioxidant prevention of diabetic complications and the impact of various therapeutic interventions.
In summary, we have shown that NIDDM is associated with increased ROOHs and low a -tocopherol which appears to be unrelated to abnormalities in lipid metabolism. An important point from our data is that ROOH levels are high even in diabetic patients without complications. We therefore suggest that oxidative stress is an early stage in the disease pathology. It pre-dates the complications, it is not simply a consequence of the complications.
